# Vitamin K Prophylaxis in Newborns: A Narrative Review of the Molecular Basis, Clinical Evidence, and Comparative Effectiveness of Intramuscular Versus Oral Administration and Parental Hesitation

**Authors:** Annamaria Mirone, Debora Mannino, Roberta Leonardi, Caterina Carpinato, Carmine Mattia, Grazia Maria Palano, Nunzia Decembrino, Martino Ruggieri, Pasqua Betta

PMC · DOI: 10.3390/ijms27041669 · International Journal of Molecular Sciences · 2026-02-09

## TL;DR

This review explains how vitamin K prevents bleeding in newborns, comparing injection and oral methods and addressing parental concerns.

## Contribution

The paper provides a translational framework linking molecular mechanisms to clinical outcomes in vitamin K prophylaxis for newborns.

## Key findings

- Intramuscular vitamin K provides more reliable protection against deficiency bleeding than oral administration.
- Parental refusal of intramuscular vitamin K increases the risk of preventable severe bleeding in newborns.
- Molecular and pharmacokinetic factors influence the effectiveness of different vitamin K administration routes.

## Abstract

Vitamin K prophylaxis represents a paradigmatic example of how molecular mechanisms directly translate into effective neonatal preventive care. In newborns, physiological immaturity of vitamin K metabolism, including limited placental transfer, low hepatic reserves, immature intestinal absorption, and dependence on vitamin K-dependent γ-carboxylation pathways, creates a unique vulnerability to vitamin K deficiency bleeding (VKDB). This narrative review integrates molecular and biochemical mechanisms with neonatal physiology and clinical evidence to examine the effectiveness of current prophylactic strategies. At the molecular and pharmacokinetic level, intramuscular (IM) administration ensures sustained bioavailability and reliable activation of vitamin K-dependent proteins, whereas oral regimens are more sensitive to formulation, dosing schedules, and absorption efficiency. Consistently, clinical and surveillance data demonstrate near-complete protection against both classic and late VKDB following IM prophylaxis, while oral approaches show greater variability, particularly in real-world settings. Importantly, increasing parental refusal of IM vitamin K undermines an intervention with well-established molecular efficacy, contributing to preventable severe bleeding events. By linking mechanistic foundations to clinical outcomes and implementation challenges, this review provides a translational framework for clinicians, researchers, and policymakers aiming to optimize neonatal vitamin K prophylaxis in contemporary practice.

## Linked entities

- **Chemicals:** vitamin K (PubChem CID 5280483)

## Full-text entities

- **Genes:** APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, F7 (coagulation factor VII) [NCBI Gene 2155] {aka SPCA}, CYP4F2 (cytochrome P450 family 4 subfamily F member 2) [NCBI Gene 8529] {aka CPF2}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, LDLR (low density lipoprotein receptor) [NCBI Gene 3949] {aka LDLCQ2}, CYP2C18 (cytochrome P450 family 2 subfamily C member 18) [NCBI Gene 1562] {aka CPCI, CYP2C, CYP2C17, P450-6B/29C, P450IIC17}, LRP1 (LDL receptor related protein 1) [NCBI Gene 4035] {aka A2MR, APOER, APR, CD91, DDH3, IGFBP-3R}, MGP (matrix Gla protein) [NCBI Gene 4256] {aka GIG36, MGLAP, NTI}, PROS1 (protein S) [NCBI Gene 5627] {aka PROS, PS21, PS22, PS23, PS24, PS25}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, VKORC1 (vitamin K epoxide reductase complex subunit 1) [NCBI Gene 79001] {aka EDTP308, MST134, MST576, VKCFD2, VKOR}, CYP2C9 (cytochrome P450 family 2 subfamily C member 9) [NCBI Gene 1559] {aka CPC9, CYP2C, CYP2C10, CYPIIC9, P450-2C9, P450IIC9}, APOB (apolipoprotein B) [NCBI Gene 338] {aka FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, BGLAP (bone gamma-carboxyglutamate protein) [NCBI Gene 632] {aka BGP, OC, OCN}, GGCX (gamma-glutamyl carboxylase) [NCBI Gene 2677] {aka VKCFD1, VKGC}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, LPA (lipoprotein(a)) [NCBI Gene 4018] {aka AK38, APOA, LP}, PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3) [NCBI Gene 5209] {aka IPFK2, PFK2, iPFK-2}, PDGFRB (platelet derived growth factor receptor beta) [NCBI Gene 5159] {aka CD140B, IBGC4, IMF1, JTK12, KOGS, OPDKD}, MTTP (microsomal triglyceride transfer protein) [NCBI Gene 4547] {aka ABL, MTP}
- **Diseases:** bleeding (MESH:D006470), hypoxic (MESH:D002534), intraventricular hemorrhage (MESH:D000074042), injury to the blood vessels (MESH:D009383), intracranial hemorrhage (MESH:D020300), microcephaly (MESH:D008831), bleeding tendency (MESH:C536965), acute leukemia (MESH:D015470), hypoxia (MESH:D000860), vomiting (MESH:D014839), anaphylactic shock (MESH:D000707), hematoma (MESH:D006406), bile salt deficiency (MESH:D013651), cerebral palsy (MESH:D002547), inflammation (MESH:D007249), abscesses (MESH:D000038), birth trauma (MESH:D014947), neurodegenerative changes (MESH:D019636), VKCFD (MESH:C564741), biliary atresia (MESH:D001656), fracture (MESH:D050723), pain (MESH:D010146), cancer (MESH:D009369), ectopic calcification (MESH:D002114), VK insufficiency (MESH:D000309), kernicterus (MESH:D007647), neuroinflammation (MESH:D000090862), necrotizing enterocolitis (MESH:D020345), , abdominal (MESH:D000007), CM (MESH:C535460), biliary obstruction (MESH:D001658), hemolytic anemia (MESH:D000743), deficiency of prothrombin (MESH:D007020), post-hemorrhagic hydrocephalus (MESH:D006849), sepsis (MESH:D018805), psychomotor or cognitive delay (MESH:D003072), neurological impairment (MESH:D009422), hemorrhagic disorder (MESH:D006474), epilepsy (MESH:D004827), Nicolau syndrome (MESH:D065148), VKDB (MESH:D006475), vascular calcification (MESH:D061205), anemia (MESH:D000740), injury to vessels and nerves (MESH:D000080902), intracranial bleeding (MESH:D013345), intracerebral hemorrhage (MESH:D002543), brain damage (MESH:D001925), leukemia (MESH:D007938), VK deficiency (MESH:D007153), death (MESH:D003643), Breast Milk Deficiency (MESH:D061325), neurological damage (MESH:D020196), brain injury (MESH:D001930), intestinal malabsorption (MESH:D008286), gastrointestinal diseases (MESH:D005767), cholestasis (MESH:D002779), coagulopathy (MESH:D001778), hepatobiliary disease (MESH:D004066), tachypnea (MESH:D059246), chronic pancreatitis (MESH:D050500)
- **Chemicals:** water (MESH:D014867), phospholipid (MESH:D010743), isoprenoid (MESH:D013729), Synkavit (MESH:C023885), glutamate (MESH:D018698), aglycones (MESH:C458179), ceramides (MESH:D002518), vegetable oils (MESH:D010938), vitamin K3 (MESH:D024483), glucuronides (MESH:D020719), fat (MESH:D005223), carboxylic acid (MESH:D002264), vitamin E (MESH:D014810), pentose phosphate (MESH:D010428), MK-7 (MESH:C062629), hydroquinone (MESH:C031927), Vitamin K2 (MESH:D024482), CO2 (MESH:D002245), Vitamin K1 (MESH:D010837), sucrose (MESH:D013395), Lipid (MESH:D008055), menaquinone-4 (MESH:C030814), hydrogen (MESH:D006859), Gla (MESH:D015055), quinone (MESH:C004532), sphingolipid (MESH:D013107), reactive oxygen species (MESH:D017382), vitamin K epoxide (MESH:C016186), calcium (MESH:D002118), glucose (MESH:D005947), bile salts (MESH:D001647), sphingomyelin (MESH:D013109), 2-monoglycerides (-), disulfide (MESH:D004220), Vitamin K (MESH:D014812), fatty acids (MESH:D005227), hydroxyapatite (MESH:D017886)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12941253/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941253/full.md

## References

85 references — full list in the complete paper: https://tomesphere.com/paper/PMC12941253/full.md

---
Source: https://tomesphere.com/paper/PMC12941253